195 related articles for article (PubMed ID: 34770845)
1. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
2. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
3. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671
[TBL] [Abstract][Full Text] [Related]
4. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.
Tang X; Cao T; Zhu Y; Zhang L; Chen J; Liu T; Ming X; Fang S; Yuan YF; Jiang L; Huang JD; Guan XY
Cell Death Dis; 2020 Jul; 11(7):510. PubMed ID: 32641749
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
6. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
7. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal ScFv that bind to different functional domains of M2 and inhibit H5N1 influenza virus replication.
Pissawong T; Maneewatch S; Thueng-In K; Srimanote P; Dong-din-on F; Thanongsaksrikul J; Songserm T; Tongtawe P; Bangphoomi K; Chaicumpa W
Virol J; 2013 May; 10():148. PubMed ID: 23672256
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
[TBL] [Abstract][Full Text] [Related]
10. Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E; Gil-Moore M; Moore J; Yousif M; Adjei AA; Ding Y; Caserta J; Baldino CM; Lee KP; Gelman IH; Takabe K; Opyrchal M
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 35920189
[TBL] [Abstract][Full Text] [Related]
11. Human Monoclonal scFvs that Neutralize Fribrinogenolytic Activity of Kaouthiagin, a Zinc-Metalloproteinase in Cobra (
Khanongnoi J; Phanthong S; Reamtong O; Tungtronchitr A; Chaicumpa W; Sookrung N
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30513883
[TBL] [Abstract][Full Text] [Related]
12. Pim2 is important for regulating DNA damage response in multiple myeloma cells.
Ramachandran J; Santo L; Siu KT; Panaroni C; Raje N
Blood Cancer J; 2016 Aug; 6(8):e462. PubMed ID: 27564460
[TBL] [Abstract][Full Text] [Related]
13. Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragments.
Sadreddini S; Seifi-Najmi M; Ghasemi B; Kafil HS; Alinejad V; Sadreddini S; Younesi V; Jadidi-Niaragh F; Yousefi M
Hum Antibodies; 2015 Dec; 23(3-4):73-9. PubMed ID: 27472865
[TBL] [Abstract][Full Text] [Related]
14. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
15. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
16. Combining chemical and genetic approaches for development of responsive FRET-based sensor systems for protein kinases.
Manoharan GB; Enkvist E; Uri A
Biophys Chem; 2016 Apr; 211():39-48. PubMed ID: 26874332
[TBL] [Abstract][Full Text] [Related]
17. Engineered Human Monoclonal scFv to Receptor Binding Domain of
Densumite J; Phanthong S; Seesuay W; Sookrung N; Chaisri U; Chaicumpa W
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34064480
[TBL] [Abstract][Full Text] [Related]
18. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
19. Human Single-Chain Antibodies That Neutralize Elastolytic Activity of
Santajit S; Kong-Ngoen T; Chongsa-Nguan M; Boonyuen U; Pumirat P; Sookrung N; Chaicumpa W; Indrawattana N
Pathogens; 2021 Jun; 10(6):. PubMed ID: 34204417
[TBL] [Abstract][Full Text] [Related]
20. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
